A Korean company that has a competitive edge in the field of gene/molecular diagnostics is currently seeking partners to further expand its market in Europe. The Korean company has been aiming to become a global leader in the field of molecular diagnostics based on its Peptide Nucleic Acid (PNA) technology (which is also known as artificial genetic material) that has been drawn a huge attention among researchers as a promising material especially, for diagnostic and therapeutic use in early stage of its development.
PNA has been firstly invented by Copenhagen Inventor Group (CIG), and based on the self-developed mass production technology, this Korean company has secured the exclusive rights for its worldwide supply. Currently, the Korean company has retained the largest number of intellectual property rights on PNA and its applied technology. Based on that, the company has secured its own various source technologies that enable a multiplex target diagnosis and detecting low level of mutation or Single Nucleotide Polymorphism, SNP.
*Below is the main feature of each technology:
First representative technology (hereinafter name it “A”) is the PNA-based PCR (Polymerase Chain Reaction) Clamping that selectively amplifies only the mutated target DNA sequence while suppressing the wild type DNA sequences during the process. The technology takes full advantages of PNA probes that have strong binding affinity and specificity to its complementary strands and property of not being used at all by DNA (DeoxyriboNucleic Acid) polymerase as primer.
Another technology hereinafter named it “B” is Multiplex Melting Curve Analysis using fluorescence labeled PNA probe. Not only it allows to detect small amount of mutation with high sensitivity, but it also made it possible to find genotype multiple mutations simultaneously. This technology uses the phenomena that each probe has its own melting temperature (Tm) value for the sequence changes of the target gene.
Lastly, there’s a novel technology that integrates A and B technologies, hereinafter name it “C”. The small portion of mutant type DNA can be detected with the highest sensitivity and it makes it possible to process various genotypes of DNA simultaneously.
Following the open innovation era, the company is seeking opportunities for collaboration with various organizations worldwide, while providing its accurate genetic diagnosis technology to lead the biomaterials and genetic diagnosis market. Considering partnership types could be commercial agreement with technical assistance, license agreement or technical cooperation agreement, but any other types of partnership is open to be considered through discussions.